Emergent BioSolutions
EBS
#6766
Rank
ยฃ0.47 B
Marketcap
ยฃ8.93
Share price
-1.24%
Change (1 day)
24.48%
Change (1 year)

Emergent BioSolutions (EBS) - Cash on Hand

Cash on Hand as of September 2025 : ยฃ0.18 Billion

According to Emergent BioSolutions 's latest financial reports the company has ยฃ0.18 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Emergent BioSolutions - Cash on Hand chart (from 2004 to 2025)

Cash on Hand by year

Year Cash on Hand Change
2024-12-31ยฃ79.28 M-9.57%
2023-12-31ยฃ87.67 M-83.49%
2022-12-31ยฃ0.53 B24.45%
2021-12-31ยฃ0.42 B-6.37%
2020-12-31ยฃ0.45 B256.2%
2019-12-31ยฃ0.12 B44.77%
2018-12-31ยฃ88.39 M-33%
2017-12-31ยฃ0.13 B-40.05%
2016-12-31ยฃ0.22 B5.77%
2015-12-31ยฃ0.20 B15.47%
2014-12-31ยฃ0.18 B65.71%
2013-12-31ยฃ0.10 B24.04%
2012-12-31ยฃ87.64 M-6.61%
2011-12-31ยฃ93.84 M-15.3%
2010-12-31ยฃ0.11 B74.21%
2009-12-31ยฃ63.6 M1.91%
2008-12-31ยฃ62.41 M17.27%
2007-12-31ยฃ53.22 M36.42%
2006-12-31ยฃ39.01 M85.37%
2005-12-31ยฃ21.04 M492.37%
2004-12-31ยฃ3.55 M
2002-12-31ยฃ3.05 M-24.45%
2001-12-31ยฃ4.03 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
Merck
MRK
ยฃ13.66 B 7,319.14%๐Ÿ‡บ๐Ÿ‡ธ USA
SIGA Technologies
SIGA
ยฃ0.12 B-29.96%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
ยฃ3.33 B 1,710.34%๐Ÿ‡ฌ๐Ÿ‡ง UK
Celldex Therapeutics
CLDX
ยฃ0.43 B 137.57%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
ยฃ11.24 B 6,003.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
ยฃ1.65 B 797.35%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Soligenix
SNGX
ยฃ7.89 M-95.71%๐Ÿ‡บ๐Ÿ‡ธ USA